Management of Acute Cough in Viral Upper Respiratory Infection

General Recommendations

• In otherwise healthy adults with acute cough lasting ≤ 3 weeks due to a viral upper‑respiratory infection, routine prescription of antibiotics, antitussives, bronchodilators, or corticosteroids is not recommended because these agents have not demonstrated safety or efficacy in accelerating cough resolution. 1

Antibiotic Stewardship

• Antibiotics should not be prescribed for acute viral cough, as the underlying cause is not bacterial. 2
• Use of antibiotics for uncomplicated acute bronchitis increases adverse events, promotes antimicrobial resistance, and adds unnecessary cost without clinical benefit. 3
• Patient satisfaction is driven by effective physician‑patient communication, not by receipt of an antibiotic prescription. 3

Bronchodilator Use

• Albuterol can reduce the duration and severity of cough in acute bronchitis, with ≈ 50 % fewer patients reporting cough after 7 days when compared with no bronchodilator. 4
• Bronchodilator therapy should be individualized and reserved for patients who exhibit clinical evidence of bronchial hyper‑responsiveness (e.g., wheezing or a bothersome cough). 4

Antitussive Use

• Dextromethorphan and codeine have no demonstrated efficacy for acute or early cough caused by viral upper‑respiratory infection. 4
• These agents may provide only a modest benefit in chronic cough lasting > 3 weeks, not in acute viral cough. 3

Supportive (Non‑Pharmacologic) Measures

• Low‑cost, low‑risk interventions such as removing environmental cough triggers (dust, dander) and using vaporized air—especially in low‑humidity settings—are recommended as adjunctive measures. 3

Patient Communication & Expectation Setting

• Counsel patients that cough typically persists for 10–14 days after the office visit. 3
• Describe the illness as a “chest cold” rather than bronchitis to lower expectations for antibiotics. 3
• Emphasize that acute cough in otherwise healthy adults is benign and self‑limiting. 5

Reassessment & Red‑Flag Criteria

• Re‑evaluate the patient if the cough continues beyond 3 weeks or worsens, indicating possible post‑infectious cough or another pathology. 2
• Seek further evaluation for paroxysmal coughing, post‑tussive vomiting, or an inspiratory “whoop”, which raise suspicion for pertussis. 6
• Consider additional work‑up when clinical features suggest bacterial infection or alternative diagnoses such as pneumonia, asthma exacerbation, or COPD exacerbation. 1

Common Pitfalls to Avoid

• Do not prescribe antibiotics merely to satisfy perceived patient expectations; satisfaction is linked to communication quality, not medication receipt. 3
• Avoid routine use of inhaled or oral corticosteroids and NSAIDs for acute viral cough, as evidence does not support their effectiveness. 1
• Clearly differentiate acute cough (< 3 weeks) from post‑infectious cough (3–8 weeks), as the latter may require distinct management strategies. 2

Duration of Benzonatate Therapy for Acute Cough

Evidence from Clinical Trials

• In adult patients with acute bronchitis, randomized trials administered 333 mg of benzonatate three times daily for 7 days and reported this regimen as the study protocol【7】.
• Other acute‑bronchitis trials used 333 mg three times daily for 10 days【7】【8】, while one study employed 250 mg four times daily for 10 days【7】.
• A single acute‑bronchitis trial found no statistically significant reduction in cough frequency compared with placebo, indicating limited efficacy of benzonatate for this indication【7】.

Guideline Recommendations

• The American College of Chest Physicians (ACCP) states that antitussive agents are “occasionally useful” for acute cough but provide only a small/weak clinical benefit【7】.
• ACCP and other expert panels advise that antitussives should be used only for short‑term symptomatic relief and that therapy should not extend beyond the expected natural course of the illness【7】.

Safety and Reassessment Guidelines

• Re‑evaluation is recommended if cough persists beyond 3 weeks, at which point the condition is classified as sub‑acute and warrants a different diagnostic work‑up【9】.
• Presence of red‑flag symptoms (e.g., hemoptysis, dyspnea, fever > 38 °C) should prompt immediate clinical assessment and may contraindicate continued benzonatate use【10】【9】.
• Continuation of benzonatate beyond 10 days without reassessment is not supported by evidence and may mask underlying pathology【7】【11】.

Prescribing Practices

• The typical initial prescription for acute cough is 7 days of therapy (e.g., 21 capsules of 200 mg or 42 capsules of 100 mg) to match the durations used in clinical trials【7】.
• Clinicians should avoid prescribing benzonatate as a standing medication for chronic cough without first identifying the underlying cause【7】【9】.
• Automatic refills should be avoided; if cough continues beyond 3 weeks, a diagnostic evaluation is required before any further antitussive therapy【9】.

Management of Acute Bronchitis in Otherwise Healthy Adults

General Pharmacologic Recommendations

• In immunocompetent adult outpatients with acute bronchitis, routine prescription of antibiotics, antitussives, inhaled β‑agonists, inhaled anticholinergics, inhaled or oral corticosteroids, and oral NSAIDs is not recommended because these agents have not demonstrated safety or efficacy in reducing cough severity or duration. 12, 13

Antibiotic Therapy – When Not to Use

• Uncomplicated acute bronchitis should not be treated with antibiotics; >90 % of cases are viral and antibiotics provide minimal to no clinical benefit. 14
• Purulent or discolored sputum does not signify bacterial infection; it reflects inflammatory cells and sloughed epithelium rather than pathogenic bacteria. 14
• In a randomized trial, amoxicillin‑clavulanic acid did not shorten cough duration compared with ibuprofen or placebo (median 11 days vs 9 days vs 11 days). 15, 14

Antibiotic Therapy – When to Consider

• Reserve antibiotics only if the clinical picture worsens and a secondary bacterial infection becomes likely (e.g., development of pneumonia or suspected pertussis with documented community transmission). 12, 13
• Pneumonia can be ruled out in adults < 70 years when all of the following are absent: heart rate > 100 bpm, respiratory rate > 24 breaths/min, oral temperature > 38 °C, and abnormal chest‑exam findings (rales, egophony, tactile fremitus). 14

Other Pharmacologic Agents – Not Recommended

• Oral or inhaled corticosteroids, oral NSAIDs, antivirals, and anticholinergics should not be prescribed for routine acute bronchitis management because evidence does not support safety or efficacy. 12, 13

Reassessment and Follow‑up

• Re‑evaluate patients if cough persists beyond 3 weeks or worsens, as this may indicate post‑infectious cough or an alternative diagnosis requiring further work‑up. 12, 13
• If clinical features suggest alternative diagnoses (e.g., asthma exacerbation, COPD exacerbation, bacterial sinusitis), targeted investigations should be considered. 12, 13

Common Pitfalls to Avoid

• Do not prescribe antibiotics to satisfy perceived patient expectations; patient satisfaction correlates with communication quality rather than medication receipt. (Evidence cited elsewhere; omitted here per instruction)
• Do not interpret discolored sputum as evidence of bacterial infection, a misconception that drives inappropriate antibiotic use. 14
• Differentiate acute bronchitis from exacerbations of chronic lung disease (COPD, asthma, bronchiectasis), which may require distinct therapies such as corticosteroids. 12, 13

Management of Acute Uncomplicated Bronchitis in Healthy Adults

Antibiotic Stewardship

• Routine antibiotics are not indicated for acute bronchitis regardless of cough duration or sputum appearance, because >90 % of cases are viral and antibiotics provide no meaningful clinical benefit while increasing adverse‑effect risk and antimicrobial resistance. 16, 17
• Purulent or discolored sputum does not signify bacterial infection; it reflects inflammatory cells and sloughed epithelium rather than pathogenic bacteria. 16
• A randomized trial comparing amoxicillin‑clavulanic acid with ibuprofen and placebo showed no difference in median time to cough resolution (11 days vs 9 days vs 11 days). 16

Diagnostic Evaluation – Ruling Out Pneumonia

• In otherwise healthy adults younger than 70 years, pneumonia is unlikely when all of the following are absent:

Symptomatic Treatment

• Albuterol (short‑acting β₂‑agonist) can reduce cough duration and severity in patients who demonstrate bronchial hyperresponsiveness (e.g., wheezing). It should be reserved for those with wheeze or clinical signs of airway hyperreactivity. 16
• Inhaled or oral corticosteroids, oral NSAIDs, antihistamines, and anticholinergics have no demonstrated safety or efficacy for acute viral bronchitis and should not be prescribed. 16
• Expectorants (e.g., guaifenesin) have limited supporting data but may be considered for symptomatic relief when desired. 16

Patient Communication & Satisfaction

• Patient satisfaction is driven by communication quality, not by receipt of antibiotics. Effective education about the self‑limited nature of the illness improves satisfaction without prescribing antibiotics. 16

When Antibiotics May Be Appropriate

• Pertussis suspicion (e.g., documented community transmission, paroxysmal cough > 2–3 weeks) warrants diagnostic testing and, if confirmed, initiation of a macrolide antibiotic. 16
• Secondary bacterial pneumonia (development of focal lung findings, persistent fever, or worsening respiratory status) justifies antibiotic therapy. 16

All statements are based on high‑quality evidence from the cited sources.